- World Vaccine Congress to present new data on combination vaccine against COVID-19 and seasonal influenza
- Several talks and presentations are planned to provide an update on NVX-CoV2373, Novavax’s COVID-19 vaccine.
GAITHERSBURG, Maryland, April 19, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will present data from its trials on the combination vaccine against COVID-19 influenza and on the vaccine against seasonal influenza, during the World Vaccine Congress (WVC) to be held at Washington, D.C.April 18-21, 2022. In addition, the latest data on NVX-CoV2373, its protein vaccine candidate against COVID-19, will be presented at the WVC and the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Lisbon, PortugalApril 23-26, 2022. Data from eight talks and presentations, including four oral presentations, will be presented at both congresses.
The doctor Gregory M. Glenn, President of Research and Development of Novavax, said: “Our presence at these two major industry conferences shows our continued commitment to addressing the issue of COVID-19, and the advances we have made towards a vaccine. next generation anti-influenza. We look forward to sharing these updates which further demonstrate the potential of our platform. »
Main presentations of Novavax during the WVC:
|
Glenn, G. |
How long will our immunity to COVID-19 last? |
panel April 19, 2022 8:45 a.m. – 9:45 a.m. ET |
|
Kim, D. |
Monitoring the Safety of COVID-19 Vaccines |
panel April 20, 2022 12:10 – 1:10 p.m. ET |
|
Glenn, G. |
Clinical Update on Recombinant Nanoparticle Protein Subunit |
Oral Session on COVID-19 and beyond – M4 April 20, 2022 12:40 – 12:00 ET |
|
Shinde, V |
NanoFlu* Vaccine Development Update |
Oral Influenza and Respiratory Illness Session – M4 April 20, 2022 12:40 p.m. – 1:10 p.m. ET |
*NanoFlu identifies an influenza vaccine candidate based on recombinant hemagglutinin (HA) nanoparticles produced by Novavax. This investigational candidate was evaluated in a phase 3 controlled trial conducted during the 2019-2020 influenza season.
Key Novavax presentations during ECCMID:
|
Toback, S |
Continued Safety and Effectiveness of the NVX-CoV2373 Vaccine |
Presentation No. 04525 Oral Breaking news session on COVID vaccination April 25, 2022 16:15 – 17:15 CET |
|
Shinde, V |
Long-term durability of polyfunctional CD4+ T cell responses |
Presentation No. 1197 Oral Session Viral respiratory infections: Influenza and RSV April 26, 2022 11:00 – 12:00 CET |
|
Áñez, G |
Safety, efficacy and performance of an adjuvanted vaccine based on |
Presentation No. 04455 Attach Session 12g. Vaccine development, trials, efficacy, policy April 25, 2022 12:00 – 13:00 CET |
|
Áñez, G |
Molecular epidemiology of SARS-CoV-2 strains identified in a phase III efficacy and safety trial |
Presentation No. 00284 Attach Session 12l. Evolution, variants and impact of the virus April 25, 2022 12:00 – 13:00 CET |
|
Beyhaghi, H |
Declared pregnancies and associated results within the framework |
Presentation No. 01705 Attach Session 12g. Vaccine development, trials, efficacy, policy April 25, 2022 12:00 – 13:00 CET |
|
Marchese, A. |
COVID-19 Vaccine Receptivity and Preferences Among |
Presentation No. 04362 Attach Session 12g. Vaccine development, trials, efficacy, policy April 25, 2022 12:00 – 13:00 CET |
For more information or to register, visit the websites of the World Vaccine Congress Washington 2022 and 32nd European Congress of Clinical Microbiology and Infectious Diseases.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved global health through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The Company’s patented recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address pressing global health needs. NVX-CoV2373, the company’s COVID-19 vaccine, has been cleared by multiple regulatory agencies globally, including conditional marketing authorization from the European Commission and the Organization World Health. The vaccine is also under review by multiple regulatory agencies around the world. In addition to its COVID-19 vaccine, Novavax is currently evaluating a combination COVID seasonal influenza vaccine in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and its experimental quadrivalent influenza vaccine, previously called NanoFlu. These vaccine candidates incorporate Novavax’s saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
To learn more, visit www.novavax.com and follow the company on LinkedIn.
contacts:
Investors
Erika Schultz | 240-268-2022
ir@novavax.com
Media
Ali Chartan | 240-720-7804
Laura Keenan Lindsey | 202-709-7521
media@novavax.com
